|  Help  |  About  |  Contact Us

Publication : SOST/Sclerostin Improves Posttraumatic Osteoarthritis and Inhibits MMP2/3 Expression After Injury.

First Author  Chang JC Year  2018
Journal  J Bone Miner Res Volume  33
Issue  6 Pages  1105-1113
PubMed ID  29377313 Mgi Jnum  J:267286
Mgi Id  MGI:6220554 Doi  10.1002/jbmr.3397
Citation  Chang JC, et al. (2018) SOST/Sclerostin Improves Posttraumatic Osteoarthritis and Inhibits MMP2/3 Expression After Injury. J Bone Miner Res 33(6):1105-1113
abstractText  Patients with anterior cruciate ligament (ACL) rupture are two times as likely to develop posttraumatic osteoarthritis (PTOA). Annually, there are approximately 900,000 knee injuries in the United States, which account for approximately 12% of all osteoarthritis (OA) cases. PTOA leads to reduced physical activity, deconditioning of the musculoskeletal system, and in severe cases requires joint replacement to restore function. Therefore, treatments that would prevent cartilage degradation post-injury would provide attractive alternatives to surgery. Sclerostin (Sost), a Wnt antagonist and a potent negative regulator of bone formation, has recently been implicated in regulating chondrocyte function in OA. To determine whether elevated levels of Sost play a protective role in PTOA, we examined the progression of OA using a noninvasive tibial compression overload model in SOST transgenic (SOST(TG) ) and knockout (Sost(-/-) ) mice. Here we report that SOST(TG) mice develop moderate OA and display significantly less advanced PTOA phenotype at 16 weeks post-injury compared with wild-type (WT) controls and Sost(-/-) . In addition, SOST(TG) built approximately 50% and approximately 65% less osteophyte volume than WT and Sost(-/-) , respectively. Quantification of metalloproteinase (MMP) activity showed that SOST(TG) had approximately 2-fold less MMP activation than WT or Sost(-/-) , and this was supported by a significant reduction in MMP2/3 protein levels, suggesting that elevated levels of SOST inhibit the activity of proteolytic enzymes known to degrade articular cartilage matrix. Furthermore, intra-articular administration of recombinant Sost protein, immediately post-injury, also significantly decreased MMP activity levels relative to PBS-treated controls, and Sost activation in response to injury was TNFalpha and NF-kappaB dependent. These results provide in vivo evidence that sclerostin functions as a protective molecule immediately after joint injury to prevent cartilage degradation. (c) 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

8 Bio Entities

0 Expression